Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Rating of “Moderate Buy” by Analysts

Relay Therapeutics, Inc. (NASDAQ:RLAY) has been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.5714.

A number of analysts have recently weighed in on the company. Wells Fargo & Company raised Relay Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $6.00 to $13.00 in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Oppenheimer upgraded Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target on the stock in a report on Monday, January 26th.

Relay Therapeutics Price Performance

Shares of NASDAQ RLAY opened at $8.93 on Friday. The stock has a market capitalization of $1.55 billion, a P/E ratio of -5.10 and a beta of 1.59. Relay Therapeutics has a one year low of $1.77 and a one year high of $9.54. The firm’s 50 day simple moving average is $8.14 and its two-hundred day simple moving average is $6.34.

Insider Transactions at Relay Therapeutics

In related news, insider Donald A. Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the sale, the insider directly owned 422,733 shares in the company, valued at $3,221,225.46. The trade was a 4.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Peter Rahmer sold 11,684 shares of the business’s stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $7.62, for a total transaction of $89,032.08. Following the sale, the insider owned 277,964 shares in the company, valued at approximately $2,118,085.68. This trade represents a 4.03% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 93,302 shares of company stock valued at $724,355. Insiders own 4.87% of the company’s stock.

Institutional Investors Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Torren Management LLC purchased a new stake in Relay Therapeutics during the 4th quarter valued at $30,000. FNY Investment Advisers LLC lifted its holdings in Relay Therapeutics by 100.0% in the second quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock valued at $34,000 after acquiring an additional 5,000 shares during the period. Quinn Opportunity Partners LLC bought a new stake in shares of Relay Therapeutics during the 2nd quarter valued at about $35,000. Smartleaf Asset Management LLC increased its position in shares of Relay Therapeutics by 288.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after purchasing an additional 3,287 shares during the last quarter. Finally, May Hill Capital LLC bought a new position in shares of Relay Therapeutics in the 2nd quarter worth approximately $38,000. Institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.